PURE Bioscience  

(Public, OTCMKTS:PURE)   Watch this stock  
Find more results for NASDAQ:PURE
-0.06 (-5.08%)
Delayed:   12:49PM EST
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 1.10 - 1.16
52 week 0.34 - 1.55
Open 1.16
Vol / Avg. 73,122.00/150,611.00
Mkt cap 67.60M
P/E     -
Div/yield     -
EPS -0.21
Shares 59.85M
Beta -0.62
Inst. own 1%
Mar 2, 2016
Q2 2016 PURE Biosciences Inc Earnings Release (Estimated) Add to calendar
Dec 10, 2015
Q1 2016 PURE Biosciences Inc Earnings Call
Dec 10, 2015
Q1 2016 PURE Biosciences Inc Earnings Release

Key stats and ratios

Q4 (Oct '15) 2015
Net profit margin -1516.13% -1046.23%
Operating margin -1001.08% -1048.01%
EBITD margin - -1019.75%
Return on average assets -204.02% -297.93%
Return on average equity -864.09% -635.58%
Employees 11 -
CDP Score - -


EL CAJON, CA 92020
United States - Map
+1-619-5968600 (Phone)
+1-619-5968690 (Fax)

Website links


Pure Bioscience, Inc. is focused on developing and commercializing antimicrobial products primarily in the food safety arena that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on patented stabilized ionic silver, and initial products contain silver dihydrogen citrate (SDC). SDC is manufactured as a liquid delivered in various concentrations. The Company currently manufactures and distributes SDC-based disinfecting and sanitizing products, which are registered by the Environmental Protection Agency (EPA).

Officers and directors

David Pfanzelter Independent Chairman of the Board
Age: 59
Henry R. Lambert Chief Executive Officer, Director
Age: 62
Mark Elliott Chief Financial Officer, Chief Accounting Officer, Vice President - Finance
Age: 40
Gary D Cohee Director
Age: 68
Tom Y Lee CPA Director
William Otis Independent Director
Age: 57
David M. Theno Jr. Ph.D. Independent Director
Age: 62